Topas Therapeutics
Founded 2016 · 22 employees on LinkedIn · 5 known investors
Find your way into Topas Therapeutics
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.
Founders & leadership
Investors · 5
Founder mafia
2 people who came through Topas Therapeutics went on to found or lead other companies.
Competitors · 3
by search overlap
Topaz Tx3 shared keywordsTopaz Therapeutics is developing a platform of next-generation oncology drugs.
Aptose Biosciences Inc.3 shared keywordsAptose Biosciences is a biopharmaceutical company developing novel cancer therapeutics, with a focus on acute myeloid leukemia treatments. The company is advancing tuspetinib through clinical trials for AML indications.
Topo Therapeutics3 shared keywordsTopo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases. It is built around scientific advisors and leadership with expertise in ion channel biology and biophysics.
Companies competing with Topas Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Topas Therapeutics do?
- Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.
- Who are Topas Therapeutics's investors?
- Topas Therapeutics's investors include EMBL Ventures, Boehringer Ingelheim Venture Fund, Gimv, BioMedPartners, Epidarex Capital.